secwatch.observer — SEC 8-K summary
======================================

Issuer:     Denali Therapeutics Inc. (DNLI)
CIK:        0001714899
Form:       8-K
Filed at:   2026-06-18T12:01:46+00:00
Accession:  0001714899-26-000081
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Denali sells Rare Pediatric Disease PRV for $195M to fund pipeline
------------------------------------------------------------------

- Gross proceeds of $195M from sale of PRV awarded after FDA approval of AVLAYAH for Hunter syndrome in March 2026.
- Proceeds to advance clinical pipeline including DNL126 (MPS IIIA), DNL593 (FTD), DNL952 (Pompe), DNL628 (Alzheimer's).
- Transaction subject to HSR waiting period; expected to close after customary conditions.
- Denali's TV platform enabled AVLAYAH, first FDA-approved biologic to cross blood-brain barrier via transferrin receptor.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1714899/000171489926000081/0001714899-26-000081-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1714899/000171489926000081/dnli-20260612.htm
  HTML page:      https://secwatch.observer/filing/0001714899-26-000081

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer